£885.00

It has never been this cheap. We have no record of a lower price.

£885 today · cheaper than every other day in the last 3 months

The 2026-2031 World Outlook for Rheumatoid Arthritis Drugs

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 63 days · 63 data points (no recent data)

Historical
Generating forecast…
£885.00 £840.75 £858.45 £876.15 £893.85 £911.55 £929.25 22 August 2026 06 September 2026 22 September 2026 07 October 2026 23 October 2026
View at Amazon ↗

Price data last checked 28 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 63 days • 1 price levels

Days at Price
63 days 0 16 32 47 63 £885 Days at Price

Price Analysis

Most common price: £885 (63 days, 100.0%)

Price range: £885 - £885

Price levels: 1 different prices over 63 days

Description

This study covers the world outlook for rheumatoid arthritis drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of rheumatoid arthritis drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Ablynx, Alder Biopharmaceuticals, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Eli Lilly, Galapagos, Genentech (Roche), Gilead Sciences, Inc., GlaxoSmithKline Plc (UK), Janssen Biotech, MedImmune, Merck, Pfizer, Regeneron Pharmaceuticals, Sanofi, and UCB. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2025).

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
04 June 2025
Listed Since
29 August 2025

Similar Products You Might Like

The 2027-2032 World Outlook for Drugs for Rheumatoid Arthritis
96% match

The 2027-2032 World Outlook for Drugs for Rheumatoid Arthritis

£890.00 30 Oct 2026
The 2026-2031 World Outlook for Anticoagulant Drugs
95% match

The 2026-2031 World Outlook for Anticoagulant Drugs

£885.00 22 Oct 2026
The 2026-2031 World Outlook for Artificial Intelligence in Medicines
95% match

The 2026-2031 World Outlook for Artificial Intelligence in Medicines

£885.00 26 Oct 2026
The 2026-2031 World Outlook for Local Anesthesia Drugs
94% match

The 2026-2031 World Outlook for Local Anesthesia Drugs

£885.00 24 Oct 2026
The 2026-2031 World Outlook for Interventional Radiology Products
94% match

The 2026-2031 World Outlook for Interventional Radiology Products

£885.00 12 Nov 2026
The 2026-2031 World Outlook for Cardiac Rhythm Management
94% match

The 2026-2031 World Outlook for Cardiac Rhythm Management

£885.00 27 Oct 2026
The 2026-2031 World Outlook for Lubricating Eye Drops
93% match

The 2026-2031 World Outlook for Lubricating Eye Drops

£885.00 21 Oct 2026
The 2026-2031 World Outlook for Exocrine Pancreatic Insufficiency Therapeutics
93% match

The 2026-2031 World Outlook for Exocrine Pancreatic Insufficiency Therapeutics

£885.00 25 Oct 2026
The 2026-2031 World Outlook for Clostridium Diagnostics
93% match

The 2026-2031 World Outlook for Clostridium Diagnostics

£885.00 23 Oct 2026
The 2026-2031 World Outlook for Glycine
93% match

The 2026-2031 World Outlook for Glycine

£885.00 12 Nov 2026
The 2026-2031 World Outlook for Articulated Automotive Robots
93% match

The 2026-2031 World Outlook for Articulated Automotive Robots

£885.00 27 Oct 2026
The 2026-2031 World Outlook for Cardiac Monitoring and Cardiac Rhythm Management
93% match

The 2026-2031 World Outlook for Cardiac Monitoring and Cardiac Rhythm Management

£885.00 02 Nov 2026
The 2026-2031 World Outlook for Butanes
93% match

The 2026-2031 World Outlook for Butanes

£885.00 21 Oct 2026
The 2026-2031 World Outlook for L-Citrulline
93% match

The 2026-2031 World Outlook for L-Citrulline

£885.00 26 Oct 2026
The 2026-2031 World Outlook for Naphtha
93% match

The 2026-2031 World Outlook for Naphtha

£885.00 24 Oct 2026
The 2026-2031 World Outlook for Formaldehydes
93% match

The 2026-2031 World Outlook for Formaldehydes

£885.00 09 Sep 2026
The 2026-2031 World Outlook for Metalworking Fluids Biocides
92% match

The 2026-2031 World Outlook for Metalworking Fluids Biocides

£885.00 27 Oct 2026
The 2026-2031 World Outlook for Freeze Drying
92% match

The 2026-2031 World Outlook for Freeze Drying

£885.00 27 Oct 2026
The 2026-2031 World Outlook for Ethylene Methyl Acrylates
92% match

The 2026-2031 World Outlook for Ethylene Methyl Acrylates

£885.00 22 Oct 2026
The 2026-2031 World Outlook for Heat Shields
92% match

The 2026-2031 World Outlook for Heat Shields

£885.00 27 Oct 2026
The 2026-2031 World Outlook for Mixed Nocturia
92% match

The 2026-2031 World Outlook for Mixed Nocturia

£885.00 22 Oct 2026
The 2026-2031 World Outlook for Skin Rejuvenation
92% match

The 2026-2031 World Outlook for Skin Rejuvenation

£885.00 27 Oct 2026
The 2026-2031 World Outlook for Epinephrine Autoinjectors with 0.15gm Dosage
92% match

The 2026-2031 World Outlook for Epinephrine Autoinjectors with 0.15gm Dosage

£885.00 30 Oct 2026
The 2026-2031 World Outlook for Hyaluronic Acid Based Dermal Fillers
92% match

The 2026-2031 World Outlook for Hyaluronic Acid Based Dermal Fillers

£885.00 30 Oct 2026